arrow
P

Paolo Chiodini

university of campania luigi vanvitelli
H指数:66
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The association between androgenic profile and cardiometabolic risk factors in young men: insights from a large observational cohort study

雄激素特征与年轻男性心血管代谢风险因素之间的关联:来自一项大型观察性队列研究的见解

2026-10-060
OAAI
One-Year Nutritional and Metabolic Changes in Patients on Incremental Peritoneal Dialysis Under Different Protein Diets: A Multicenter Pragmatic Cohort Study

不同蛋白饮食下增量腹膜透析患者一年营养与代谢变化:一项多中心实用队列研究

2026-08-110
OA
Semen Quality in a Large Cohort of Males Living in Highly Polluted Areas of Campania Region in Southern Italy with a Focus on the Role of Cadmium Exposure

意大利南部坎帕尼亚地区高污染区域居住的男性大型队列中的精子质量,并重点探讨镉暴露的作用

2026-06-250
OAAI
Cancer in migrant populations: evidence from a regional oncology network

移民人群中的癌症:区域性肿瘤网络证据

2026-04-090
OAAI
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
The Impact of body mass index on Survival and Surgical Outcomes in Ovarian Cancer: Insights from the MITO Trials

体重指数对卵巢癌患者生存及手术结果的影响:来自MITO试验的见解

2025-11-010
PRE
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

HR+/HER2−转移性乳腺癌患者在CDK4/6抑制剂进展后接受全身治疗的疗效与安全性:一项系统评价和网络荟萃分析

2025-09-300
OAAI
Impact of Empagliflozin as add-on to Metformin vs Metformin continuation on MASLD Progression in Type 2 Diabetes: The IMAGIN Study

伊格列净作为二甲双胍加用药物与继续使用二甲双胍对2型糖尿病MASLD进展的影响:IMAGIN研究

2025-08-230
PRE
Changes in 24-hour blood pressure profile after 12 weeks of dapagliflozin treatment in patients with diabetic kidney disease: an Italian multicenter prospective study
2024-10-170
OAAI
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study

接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

2024-10-160
OAAI
Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review
2024-05-013
OAAI
Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: the MITO-16A/MANGO-OV2A clinical trial experience
2024-03-040
PRE